Cure Today12d
Blenrep-Based Combo Provides Survival Benefit in Relapsed/Refractory Multiple Myeloma
Findings from a phase 3 trial with Blenrep, Velcade and dexamethasone in relapsed/refractory multiple myeloma will be ...
Zacks.com on MSN4d
FDA Accepts GSK's BLA for Blenrep Combos in Multiple Myeloma
The FDA accepts GSK's BLA seeking approval of Blenrep combinations for treating relapsed/refractory multiple myeloma. A decision is due on July 23, 2025.
GSK's Blenrep treatment accepted for review by FDA
Pharma titan GSK has announced that US regulators have accepted for review Blenrep combinations for the treatment of relapsed ...
GSK :FDA Accepts Blenrep Combination For Review In Treatment Of Relapsed/Refractory Multiple Myeloma
GSK plc (GSK, GSK.L) announced that the US Food and Drug Administration has accepted for review a Biologics License Application (BLA) ...
Daily4d
USFDA accepts for review application for GSK Blenrep combinations for multiple myeloma treatment
London: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review a Biologics License ...
GSK’s Blenrep Nears FDA Review for Myeloma
GlaxoSmithKline (GB:GSK) has released an update.Don't Miss our Black Friday Offers:Unlock your investing potential with TipRanks Premium - Now ...
Nasdaq4d
FDA Accepts GSK's BLA for Blenrep Combos in Multiple Myeloma
GSK plc GSK announced that the FDA accepted its biologics license application (BLA) seeking approval for the Blenrep (belantamab mafodotin) combination therapy to treat relapsed or refractory ...
London South East5d
Blenrep combinations accepted for US FDA review
Regulatory submission supported by phase III head-to-head DREAMM-7 and DREAMM-8 trials showing statistically significant efficacy, including overall survival in DREAMM-7 · If approved ...
The Pharma Letter15d
Blenrep results ‘transformative’, GSK says
UK drugmaker GSK might be trading lower following Thursday’s nomination of vaccine sceptic Robert F Kennedy Jr as the USA’s ...